Journals By Industry - Enzyme Inhibitors

The week 12 disease control rate (PR and SD at week 12) was 68%. Evidence of objective tumor regression was observed in 78% of patients, including those with or without prior sorafenib therapy....

CAMBRIDGE, Mass. -- Millennium: The Takeda Oncology Company today announced it has been named among the 100 Best Companies to Work For in the United States by FORTUNE. This is the second consecutive...

Standard Use of Rave by Japanese Specialty Pharma Across All Trials Will Streamline Research, Accelerate Decision Making and Help Expand Global Network NEW YORK & OSAKA, Japan -- Medidata Solutions (NASDAQ: MDSO), a...

Study also Demonstrated 100% Sustained Virologic Response 12-Weeks Post Treatment with Quadruple Therapy Phase II Investigational Data Published Today in the New England Journal of Medicine PRINCETON, N.J. -- Bristol-Myers Squibb Company (NYSE:...

ROCHESTER, Minn. -- An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were...

CAMBRIDGE, Mass. -- Constellation Pharmaceuticals, Inc., today announced that it has entered into a major strategic agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to launch a...

NEW YORK -- Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that reported earnings per share were $1.04 in the third quarter of fiscal 2012. Reported earnings per...

WOBURN, Mass. -- ArQule, Inc. (NASDAQ: ARQL) today announced that treatment with tivantinib as single agent therapy produced a statistically significant 56 percent improvement in time-to-progression (TTP) in the intent-to-treat (ITT) population, the...

SOUTH SAN FRANCISCO, Calif. -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced it will make its first milestone payment to ForSight VISION4, Inc. as part of...

- Partnership Includes US Profit Share and Co-Promotion Option for Epizyme - CAMBRIDGE, Mass. -- Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer patients, today announced...

This new indication is based on the evaluation of safety, tolerability, pharmacokinetic parameters and efficacy of ISENTRESS through at least 24-weeks, in a multicenter, open-label, non-comparative study, in HIV-1-infected children and adolescents two...

One of the world's largest pharmaceutical players, Takeda Pharmaceutical Co. Ltd., is gobbling up La Jolla-based drug-development company Intellikine inc., the two companies said. Osaka, Japan-based Takeda said it will purchase Intellikine for...

BERGEN, Norway -- BerGenBio AS, an emerging oncology biopharma company, today announced it has completed an $8.8 million Series A financing round. The financing will be used primarily to take lead compound BGB324...

* Confirmation of favorable BCX4208 safety profile through 24 weeks * Proportion of patients reaching serum uric acid goal sustained at 24 weeks * BioCryst to host a conference call & webcast Monday,...

SOUTH SAN FRANCISCO, Calif. -- Tobira Therapeutics, Inc. announces the appointment of Eric Lefebvre, M.D., as Chief Medical Officer, and Martine Kraus, Ph.D., as Vice President, Regulatory Affairs. Both appointments are effective immediately....

FORT WASHINGTON, Pa. -- Vitae Pharmaceuticals today announced it will present at the JP Morgan Healthcare Conference on Thursday, January 12, 2012 at 9:30 a.m. Pacific Time in San Francisco, CA. Vitae's President...

* Partnership is based on Oncodesign's Nanocyclix([R])Technology for next generation kinase inhibitors and Ipsen's expertise in Movement Disorders DIJON, France & PARIS -- Regulatory News: Oncodesign, a Drug Discovery company and Oncology pharmacology...

LOS ANGELES -- Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at 1:00...

Company Starts Clinical Studies with Its Oral CYP17 Lyase Inhibitor for the Treatment of Castration-Refractory Prostate Cancer RESEARCH TRIANGLE PARK, N.C. -- Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a...